Synonyms: BHV-3500 | BMS-742413 | BMS742413 | Zavzpret®
zavegepant is an approved drug (FDA (2023))
Compound class:
Synthetic organic
Comment: Zavegepant is a CGRP receptor antagonist [1,3], that was developed as a drug to treat and/or prevent migraine. It was designed for intranasal administration.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Chaturvedula PV, Mercer SE, Pin SS, Thalody G, Xu C, Conway CM, Keavy D, Signor L, Cantor GH, Mathias N et al.. (2013)
Discovery of (R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide (BMS-742413): a potent human CGRP antagonist with superior safety profile for the treatment of migraine through intranasal delivery. Bioorg Med Chem Lett, 23 (11): 3157-61. [PMID:23632269] |
2. Dhillon S. (2023)
Zavegepant: First Approval. Drugs, 83 (9): 825-831. [PMID:37227596] |
3. Mercer SE, Chaturvedula PV, Conway CM, Cook DA, Davis CD, Pin SS, Macci R, Schartman R, Signor LJ, Widmann KA et al.. (2021)
Azepino-indazoles as calcitonin gene-related peptide (CGRP) receptor antagonists. Bioorg Med Chem Lett, 31: 127624. [PMID:33096162] |